bullish
CHMP Meeting Update: Five New Medicines Recommended for Approval, Rejects Kisunla Application
215 Views01 Apr 2025 23:23
CHMP recommends approval for five medicines, but rejects marketing authorization for Eli Lilly's Kisunla for early Alzheimer's disease. It also recommended indication extension for seven medicines.
What is covered in the Full Insight:
- Introduction
- New Medicines Approved
- Negative Recommendations
- Withdrawn Applications
- Other Updates
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
x